“Looking back, cancer was not talked about openly in the African American community I grew up in,” prostate cancer survivor Bin McLaurin says. “I had no real perspective on any of the symptoms that go ...

New research has identified specific blood-based biomarkers that can predict the failure of prostate cancer treatment in both hormone-sensitive and castration-resistant patients. The study ...

Generally, prostate cancer survival rates are very good with a five-year survival rate of 97%. There are, however, a number of factors that can influence survival rates, particularly for men with ...

The investigators reported that ultra-low PSA responses “were associated with prolonged rPFS and delayed progression to mCRPC and PSA progression.” ...

the size of the cancer and whether it has spread (the stage) Doctors use the Grade score or Gleason score and other information to divide prostate cancer into 5 groups. This is called the Cambridge ...

Gleason score 6 is the lowest grade of prostate cancer. This rating means that the prostate cancer is considered to be low- or very low-risk disease, or group 1. Most of these tumors are found during ...

Androgen deprivation is the mainstay of advanced prostate cancer treatment ... discusses recent and ongoing trials and offers some insights into identifying the best sequence of new drugs.

Metastasis-directed SABR has demonstrated benefit in oligometastatic castration-sensitive prostate cancer, but disease progression often occurs in bone. To assess whether adding Ra223 to SABR ...

Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than ...

It produces a more detailed picture of your prostate gland than a standard MRI scan does. You usually have an mpMRI scan if doctors suspect that you have prostate cancer. It is important to know that ...

Merck is still plugging away with Keytruda though, and has two phase 3 trials on the go – the KEYNOTE-641 in post-hormonal therapy metastatic CRPC patients, and KEYNOTE-991 in metastatic hormone ...